Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 12Brain Neoplasms 6Gliosarcoma 5Astrocytoma 4Recurrence 3Oligodendroglioma 3Lymphoma, Follicular 3Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Optic Nerve Glioma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Glioma 2Diffuse Intrinsic Pontine Glioma 2Central Nervous System Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1

Interventions

pembrolizumab 9Cisplatin 9Cetuximab 6Paclitaxel 5Radiotherapy 4Fluorouracil 4zalutumumab 3Nivolumab 3Docetaxel 3Taxes 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Gefitinib 2Cyclophosphamide 2Carboplatin 2temsirolimus 1sintilimab 1poly ICLC 1osimertinib 1fludarabine phosphate 1fludarabine 1enzalutamide 1durvalumab 1cobimetinib 1atezolizumab 1advexin 1abemaciclib 1Vorinostat 1Sorafenib 1Risk Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Squamous Cell × Cilengitide × Clear all
NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡